Henry Dunant Hospital Center

The Henry Dunant Hospital Center conducts extensive trials in non‑small cell lung cancer and small‑cell lung cancer, focusing on targeted therapies for mutations such as KRAS G12C, EGFR, and HER2, as well as novel immunotherapy combinations.

• KRAS G12C inhibitor studies in advanced disease
• EGFR‑mutated tumor targeted agents
• Immunotherapy plus chemotherapy regimens
• Neoadjuvant approaches with radiation
• Early‑stage trials integrating checkpoint inhibitors

With 89 active clinical trials and 20 investigators, the department advances treatment options for lung cancer patients across Greece.

Research at the site includes studies on hormone‑receptor positive breast cancer, triple‑negative breast cancer, and ovarian cancer, evaluating new antibody‑drug conjugates, CDK4/6 inhibitors, and immunotherapy strategies.

• Adjuvant CDK4/6 inhibitor trials
• Triple‑negative breast cancer combination therapy
• Ovarian cancer immune checkpoint studies
• Bladder cancer vaccine investigations
• Biomarker‑driven treatment arms

The oncology unit leverages multidisciplinary expertise to bring innovative options to patients with breast and gynecologic malignancies.

The center runs trials addressing acute coronary syndrome, atrial fibrillation, and type 2 diabetes, testing anti‑inflammatory antibodies, anticoagulant alternatives, and next‑generation glucose‑lowering agents.

• IL‑6 inhibition after myocardial infarction
• Novel anticoagulant for patients unsuitable for oral therapy
• Oral semaglutide efficacy in adolescents
• Cardiovascular outcome reduction with anti‑inflammatory therapy
• Metabolic risk management in post‑MI patients

These studies aim to improve survival and quality of life for cardiovascular and metabolic disease patients.

Clinical investigations focus on Alzheimer’s disease agitation, psychosis, mild cognitive impairment, and multiple sclerosis, seeking therapies that alleviate symptoms and modify disease course.

• AVP‑786 for agitation in dementia
• KarXT evaluation for psychosis associated with Alzheimer’s
• Relapse prevention with remibrutinib in multiple sclerosis
• Cognitive benefit of semaglutide in early Alzheimer’s
• Neuropsychiatric outcome measures in trial designs

The multidisciplinary team collaborates with neurology and psychiatry specialists to deliver patient‑centered research.

The hospital’s trials include work on small‑cell lung cancer, urothelial carcinoma, and other immune‑related malignancies, evaluating novel agents to boost response rates and durability.

• Combination therapy for extensive‑stage small‑cell lung cancer
• Antibody‑drug conjugate versus physician’s choice in urothelial cancer
• Checkpoint inhibitor plus novel immunomodulator studies
• Therapeutic cancer vaccine OSE2101 compared with chemotherapy
• Biomarker‑guided enrollment for immune‑focused trials

These efforts support the development of next‑generation immunotherapies for thoracic and urinary tract cancers.